HAE
HAEMONETICS CORP
NYSE · Healthcare · Medical - Instruments & Supplies · US
$117.97
−0.64%Price chart
Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20
Key dataOct 20, 2026
Open$119.50
From 52W high−3.35%
Volume61891.00
Market cap$5.37B
P/E (TTM)57.3x
P/S (TTM)4.0x
Div yield—
Key dataOct 20, 2026
Open
$119.50
From 52W high
−3.35%
Volume
61891.00
Market cap
$5.37B
ValuationView details →
P/E (Fwd)
20.9x
EV/EBITDA
24.2x
P/E (TTM)
57.3x
RSI (14)
66.6
MomentumView details →
1D Return
−0.64%
YTD Return
+47.89%
SummaryUpdated Jun 1, 2026
Haemonetics Corporation (NASDAQ:HAE) is a Boston-based healthcare company founded in 1971 that specializes in blood and plasma management technologies. The company has evolved from its origins in blood collection to become a leading provider of automated medical devices, software systems, and disposable products that help healthcare providers and plasma collection centers manage blood components more efficiently. Haemonetics went public in 1991 and has since grown through both organic expansion and strategic acquisitions to serve three primary markets: plasma collection, blood centers, and hospitals worldwide.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration approved HAEMONETICS CORP’s PerQseal Elite vascular closure system for large-bore arterial procedures in the United States.18h agoHAEMONETICS CORP shares rose more than 13% to $115.20 on Thursday.12d agoHaemonetics Corporation announced it will publish its second quarter fiscal year 2027 financial results on November 5, 2026.20d ago